Gina Valente Moore
Family · Jamestown, CANPI 1336337484
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,680 of the $30,574 with a category attached, or 64.4%. Gilead accounts for 88.4% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $11,016, 3.4 times the $3,279 reported in 2021. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $117.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$27K
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$303
- Johnson & Johnson$240
- Corcept Therapeutics$210
- Takeda Pharmaceuticals U.S.A., Inc.$188
- plus $1K from 25 others
What the payments were for
- Speaking & faculty fees$19,68064%
- Travel & lodging$4,77816%
- Food & beverage$6,09520%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,574 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 13 | $297,859 |
| XifaxanRifaximin | 39 | $125,251 |
| Humira(Cf) PenAdalimumab | 16 | $97,958 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $37,618 |
| EliquisApixaban | 37 | $36,565 |
| OzempicSemaglutide | 41 | $35,918 |
| Nurtec OdtRimegepant Sulfate | 21 | $31,443 |
| RybelsusSemaglutide | 15 | $29,630 |
| ViberziEluxadoline | 11 | $17,304 |
| LinzessLinaclotide | 23 | $14,999 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $13,280 |
| MounjaroTirzepatide | 12 | $11,976 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $9,869 |
| OxycontinOxycodone Hcl | 14 | $8,980 |
| MovantikNaloxegol Oxalate | 21 | $8,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $27,027 | $297,85913 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $303 | $125,25139 claims |
| PfizerEliquis, Nurtec Odt | $58 | $68,00958 claims |
| Novo NordiskOzempic, Rybelsus | $53 | $65,54956 claims |
| AbbVieViberzi, Linzess | $1,481 | $32,30334 claims |
| Lilly USA, LLCMounjaro | $157 | $11,97612 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone | $21 | $8,15830 claims |
| AstraZenecaSymbicort | $51 | $3,82112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Jamestown
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.